RISE Pediatric Medication Study (RISE Peds)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The RISE Pediatric Medication Study is a 2-arm, 4-center, clinical trial of children with prediabetes and early type 2 diabetes to address the hypothesis that aggressive glucose lowering will lead to recovery of beta-cell function that will be sustained after withdrawal of treatment. Pediatric participants (ages 10-19) will be randomized to one of the following treatment regimens: (1) metformin alone or (2) early intensive treatment with basal insulin glargine followed by metformin.
The primary clinical question RISE will address is: Are improvements in ß-cell function following 12 months of active treatment maintained for 3 months following the withdrawal of therapy? Secondary outcomes will assess durability of glucose tolerance following withdrawal of therapy, and whether biomarkers obtained in the fasting state predict parameters of ß-cell function, insulin sensitivity and glucose tolerance and the response to an intervention.
| Condition | Intervention | Phase |
|---|---|---|
|
Prediabetes Type 2 Diabetes |
Drug: Metformin Drug: Glargine |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Restoring Insulin Secretion Pediatric Medication Study |
- ß-cell function measured by hyperglycemic clamp techniques [ Time Frame: 3-months after a medication washout ] [ Designated as safety issue: No ]Participants will have 12-months of active therapy and 3-months of washout after which the primary outcome will be assessed.
- Hyperglycemic clamp and oral glucose tolerance test (OGTT) measures of ß-cell Function and Glucose Tolerance [ Time Frame: 3-months after a medication washout ] [ Designated as safety issue: No ]Measures derived from the hyperglycemic clamp that are not specified as primary outcomes and measures derived from the OGTT.
- Hyperglycemic clamp and OGTT measures of ß-cell Function and Glucose Tolerance [ Time Frame: After 12 months of active treatment ] [ Designated as safety issue: No ]Measures derived from the hyperglycemic clamp and the OGTT related to treatment effect at the end of the 12 month active intervention period compared to pre-treatment baseline.
| Estimated Enrollment: | 90 |
| Study Start Date: | April 2013 |
| Estimated Study Completion Date: | August 2017 |
| Estimated Primary Completion Date: | August 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: Metformin alone
Metformin will be titrated to the maximum dose tolerated (up to 2000 mg/day).
|
Drug: Metformin
Other Name: Glucophage
|
|
Active Comparator: Glargine followed by Metformin
Basal insulin glargine for 3 months titrated to achieve a morning fasting blood glucose of 85-95 mg/dl, followed by metformin (titrated up to 2000 mg/day) for 9 months.
|
Drug: Metformin
Other Name: Glucophage
Drug: Glargine
Other Name: Insulin glargine, Lantus
|
Eligibility| Ages Eligible for Study: | 10 Years to 19 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Fasting plasma glucose ≥95 mg/dl plus 2-hour glucose ≥140 mg/dl on 75 gm OGTT plus laboratory-based HbA1c ≥5.8 and ≤8.0% if treatment naïve. There is no upper limit for the 2-hour glucose on OGTT. In those taking metformin laboratory-based HbA1c must be ≤7.5% if on metformin for <3 months and ≤7.0% if on metformin for 3-6 months.
- Age 10-19 years
- Pubertal development Tanner stage >1 as defined by breast stage >1 in girls, and testes >3 cc's in boys.
- Body mass index (BMI) ≥85th percentile but ≤40 kg/m2
- Self-reported diabetes <6 months in duration
- Treatment with metformin for <6 months preceding screening
Exclusion Criteria:
- Underlying disease likely to limit life span and/or increase risk of intervention or an underlying condition that is likely to limit ability to participate in outcomes assessment
- An underlying disease that affects glucose metabolism other than type 2 diabetes mellitus
- Taking medications that affect glucose metabolism, or has an underlying condition that is likely to require such medications
- Treatment with insulin for >1 week preceding screening
- Active infections
- Renal disease (serum creatinine >1.2 mg/dl) or serum potassium abnormality (<3.4 or >5.5 mmol/l)
- Anemia (hemoglobin <11 g/dl in girls, <12 g/dl in boys) or known coagulopathy
- Cardiovascular disease, including uncontrolled hypertension defined as average systolic or diastolic blood pressure > 99 percentile for age or >135/90, despite adequately prescribed antihypertensive medications. Participants must be able to safely tolerate administration of intravenous fluids required during clamp studies.
History of conditions that may be precipitated or exacerbated by a study drug:
- Serum alanine transaminase (ALT) more than 3 times the upper limit of normal
- Excessive alcohol intake
- Sub-optimally treated thyroid disease
Conditions or behaviors likely to affect the conduct of the RISE Study
- Participant and/or parents unable or unwilling to give informed consent
- Participant and/or parents unable to adequately communicate with clinic staff
- Another household member is a participant or staff member in RISE
- Current, recent or anticipated participation in another intervention research project that would interfere with any of the interventions/outcomes in RISE
- Weight loss of ≥5% of body weight in the past 3 months for any reason other than post-partum weight loss. Participants taking weight loss drugs or using preparations taken for intended weight loss are excluded.
- Likely to move away from participating clinics in next 2 years
- Current (or anticipated) pregnancy and lactation.
- A pregnancy that was completed less than 6 months prior to screening.
- Breast feeding within 6 months prior to screening.
- Women of childbearing potential who are unwilling to use adequate contraception
- Major psychiatric disorder that, in the opinion of clinic staff, would impede the conduct of RISE
- Additional conditions may serve as criteria for exclusion at the discretion of the local site.
Contacts and Locations| United States, Colorado | |
| Childrens Hospital Colorado | Not yet recruiting |
| Denver, Colorado, United States, 80045 | |
| Contact: Rose Moorehead 720-777-2855 Kristen.Nadeau@childrenscolorado.org | |
| Principal Investigator: Kristen Nadeau, MD | |
| United States, Connecticut | |
| Yale School of Medicine Pediatric Obesity and Type 2 Diabetes Clinic | Not yet recruiting |
| New Haven, Connecticut, United States, 06511 | |
| Contact: Bridget Pierpont, M.A. 203-785-2942 bridget.pierpont@yale.edu | |
| Principal Investigator: Sonia Caprio, MD | |
| United States, Indiana | |
| Indiana University | Not yet recruiting |
| Indianapolis, Indiana, United States, 46202 | |
| Contact: Robin Chisholm, RN 317-274-7679 rlchisho@iupui.edu | |
| Principal Investigator: Kieren Mather, MD | |
| United States, Pennsylvania | |
| Children's Hospital of Pittsburgh of UPMC | Not yet recruiting |
| Pittsburgh, Pennsylvania, United States, 15224 | |
| Contact: Kathy Brown 412-692-5846 kathleen.brown@chp.edu | |
| Principal Investigator: Silva Arslanian, MD | |
More Information
No publications provided
| Responsible Party: | RISE Study Group |
| ClinicalTrials.gov Identifier: | NCT01779375 History of Changes |
| Other Study ID Numbers: | RISE Pediatric, 5U01DK094406-02 |
| Study First Received: | January 28, 2013 |
| Last Updated: | January 28, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by RISE Study Group:
|
Children Pediatric |
Additional relevant MeSH terms:
|
Diabetes Mellitus, Type 2 Glucose Intolerance Prediabetic State Diabetes Mellitus Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
Hyperglycemia Glargine Insulin Metformin Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 22, 2013